Department of Psychiatry, Grey Nuns Community Hospital, Edmonton, Canada.
Medical and Regulatory Affairs, Lundbeck Canada Inc., Montreal, Canada.
CNS Spectr. 2019 Dec;24(6):616-627. doi: 10.1017/S1092852919000786.
AtWoRC (Assessment in Work productivity and the Relationship with Cognitive symptoms) was an interventional, open-label, Canadian study (NCT02332954) designed to assess the association between cognitive symptoms and workplace productivity in working patients with major depressive disorder (MDD) receiving vortioxetine.
Eligible patients with MDD received vortioxetine (10-20 mg/day) and were assessed over 52 weeks at visits emulating a real-life setting (n = 199). Partial correlation between changes in patient-reported cognitive symptoms (20-item Perceived Deficits Questionnaire-Depression; PDQ-D-20) and workplace productivity (Work Limitations Questionnaire; WLQ) was assessed at 12 and 52 weeks. Additional assessments included depression severity, cognitive performance, and patient-reported functioning. Structural equations model (SEM) analyses assessed causal relationships between changes in measures of cognition and functioning over time, adjusted for improvements in depressive symptoms.
Statistically significant improvements in all outcomes from baseline to week 52 were seen in the overall population and both subgroups (first treatment and switch). Response and remission rates were 77% and 56%, respectively. Improvements in PDQ-D-20 and WLQ productivity loss scores at weeks 12 and 52 were significantly correlated. SEM analyses found patient-rated cognitive symptoms (PDQ-D-20) at weeks 12 and 26 were significantly predictive (p < 0.05) of patient-reported functioning (Sheehan Disability Scale) at the subsequent visit. Depression severity and objectively measured cognitive performance did not significantly predict functional outcomes at any timepoint.
These results demonstrate the long-term benefits of vortioxetine treatment in working patients with MDD and emphasize the strong association between cognitive symptoms and functioning in a real-world setting.
AtWoRC(工作生产力评估与认知症状的关系)是一项干预性、开放性、加拿大研究(NCT02332954),旨在评估认知症状与接受文拉法辛治疗的有工作的重度抑郁症(MDD)患者的工作场所生产力之间的关系。
符合条件的 MDD 患者接受文拉法辛(10-20mg/天)治疗,并在模拟现实环境的访视中进行了 52 周的评估(n=199)。在 12 周和 52 周时,评估患者报告的认知症状(20 项感知缺陷问卷-抑郁;PDQ-D-20)和工作场所生产力(工作限制问卷;WLQ)变化之间的部分相关性。其他评估包括抑郁严重程度、认知表现和患者报告的功能。结构方程模型(SEM)分析评估了随时间推移认知和功能测量变化之间的因果关系,调整了抑郁症状的改善。
在整个人群和两个亚组(首次治疗和转换)中,从基线到第 52 周所有结局均有统计学显著改善。分别为 77%和 56%的反应率和缓解率。第 12 周和第 52 周时,PDQ-D-20 和 WLQ 生产力损失评分的改善与显著相关。SEM 分析发现,第 12 周和第 26 周时患者自评的认知症状(PDQ-D-20)显著预测(p<0.05)随后访视时的患者报告功能(Sheehan 残疾量表)。抑郁严重程度和客观测量的认知表现并不能在任何时间点显著预测功能结局。
这些结果表明文拉法辛治疗有工作的 MDD 患者的长期获益,并强调了在现实环境中认知症状与功能之间的强烈关联。